# A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

> **NCT01908829** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Europe Ltd.** · enrollment: 2174 (actual)

## Conditions studied

- Urinary Bladder Diseases
- Urinary Bladder Overactive
- Urologic Diseases

## Interventions

- **DRUG:** mirabegron 25 mg
- **DRUG:** mirabegron 50 mg
- **DRUG:** solifenacin 5 mg
- **DRUG:** solifenacin 10 mg
- **DRUG:** mirabegron 25 mg matching placebo
- **DRUG:** mirabegron 50 mg matching placebo
- **DRUG:** solifenacin 5 mg matching placebo
- **DRUG:** solifenacin 10 mg matching placebo

## Key facts

- **NCT ID:** NCT01908829
- **Lead sponsor:** Astellas Pharma Europe Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-10
- **Primary completion:** 2014-11-24
- **Final completion:** 2014-11-25
- **Target enrollment:** 2174 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01908829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01908829, "A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01908829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*